Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Biobusiness Briefs
  • Published:

Regulatory watch

Where do new medicines originate from in the EU?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Origin of new medicines in the European Union (2010–2012).

Author information

Authors and Affiliations


Corresponding author

Correspondence to Constantinos Ziogas.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (box)

Details of data and analysis (PDF 255 kb)

Supplementary information S2 (Table)

Origin of orphan and non-orphan new medicines in the EU: 2010–2012 (PDF 202 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lincker, H., Ziogas, C., Carr, M. et al. Where do new medicines originate from in the EU?. Nat Rev Drug Discov 13, 92–93 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research